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has been only one other 80% restenosis in the 70-odd patients who
have been treated after that time. We looked into the subset. In the
paper we have, indeed, reported log-rank comparisons between
survival curves of the Wallstents that we were using originally and
the nitinol stents that we are using now, as well as whether there
was a difference between post-CEA restenosis patients, whom we
were treating initially, and primary high-risk patients with symp-
toms. There were no significant differences; however, the numbers
were too low to make a definitive determination. We suspect it has
to do with the type of stent we have been using.
Dr Luis A. Queral (Baltimore, Md). I’m wondering if you
can comment on whether it’s justified to put patients with recur-
rent artery stenoses with primary disease in the same group, inas-
much as the pathogenesis seems to be somewhat different. I also
wonder whether the type of endarterectomy performed on 65% of
these patients influenced the recurrence rate, whether it was
patched or not patched, a reversion. And I know that’s an old
question in vascular surgery, but it has an impact here since that’s
the majority of your patients. And finally, can you relate the
recurrence rate to the location of this restenosis? It seems to me
that it might be a different thing to have a recurrent stenosis in the
common carotid proximal to the previously treated lesion versus
one in the internal carotid artery above the area of surgery.
Dr Lal. I think that’s an excellent question. Restenotic lesions
within a 36-month period after CEA are usually secondary to
intimal hyperplasia. And several authors have speculated that a
stent in such a lesion may induce higher rates of in-stent restenosis.
We compared the in-stent restenosis rates of our post-CEA
restenosis patients with our primary lesion patients and haven’t
noticed any difference. It may just mean that the number of
patients that we have in our group right now is too low to identify
that difference. And that’s probably the best that can be said right
now in answer to your question. Unfortunately, some of the
publications with large numbers of patients have not followed their
patients beyond 6 months.
Dr Linda Harris (Buffalo, NY). Have you looked at the
subset of patients with the primary atherosclerotic disease, which is
a different entity than restenotic lesions? What is your follow-up on
those individuals, and on the basis of that, can we say anything
about stenosis in those individuals with carotid stenting or not?
Dr Lal. The mean follow-up for our primary patients is
approximately 16 months, so it’s not very different from the mean
follow-up of our entire cohort. And again, the in-stent restenosis
rates between our primary and our restenotic patient groups are
not significantly different as yet. Two of our patients out of the
hemodynamically significant five patients had primary lesions and
three had restenotic lesions.
INVITED COMMENTARY
Kenneth Ouriel, MD
The article by Lal and colleagues represents an important
contribution to the accumulating body of knowledge upon which
clinical decisions concerning carotid angioplasty and stenting will
be made. Uniquely, this study defines the long-term incidence of
in-stent restenosis and its clinical relevance. The authors concluded
that restenosis after carotid stenting is both an infrequent event
(6% at 5 years) and one rarely associated with neurologic sequelae
(0/5 restenoses). For sure, Lal’s study has limitations. The duplex
criteria for restenotic lesions appear to be validated for primary,
nonstented carotid arteries and not for either recurrent lesions after
endarterectomy or for in-stent restenoses. The number of evalu-
able patients at 5 years is small (four patients at the 60-month time
point), the study population is skewed toward patients with reste-
nosis after carotid endarterectomy, and a majority of patients were
treated with a stent that many would consider outmoded. While
subgroup analyses failed to identify relationships between these
variables and outcome, the statistical power of these analyses was
low. Importantly, the infrequent occurrence of restensosis (5 of
122 cases) accounts for much uncertainty in the estimate of reste-
nosis-associated neurologic events. The observed frequency of
zero events in five restenotic patients does not exclude a true rate of
symptoms as high as 45% (95% confidence interval, 0%-45%).
These limitations aside, Lal’s study represents yet another
piece of the carotid stenting puzzle, providing data on the dura-
bility of the procedure. Restenosis after carotid stenting does not
appear to occur with the frequency observed in smaller vessels such
as the coronary arteries. Rather, the rate of restenosis after carotid
stenting appears analogous to that following carotid endarterec-
tomy; restenosis occurs infrequently and when it does, it often
develops silently and without symptoms. Taken in concert with the
accumulating body of evidence on the short-term safety of stent-
ing, the restenosis data add to the realization that percutaneous
carotid interventions are often reasonable alternatives to standard
carotid endarterectomy. Although this is a finding that few sur-
geons would have predicted, failure to embrace this evolving
technology risks exclusion from participation in the care of patients
with carotid disease. On the other hand, involvement in the
ongoing investigations of carotid stenting will, in the words of
Winston Churchill, ensure that “history will look favorably upon
us, for we will write it.”
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